Search

Search Results

• 

  OC03 | THROMBOEMBOLIC PREVALENCE IN MULTIPLE MYELOMA BEFORE AND AFTER THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS: A LONGITUDINAL COHORT STUDY A. Ramírez¹, A. Orozco², A. Sánchez³, F. Villalpa¹, S. Burgos², G. Cesarman³, G. Rodríguez¹, D. Vieyra², J. Álvarez⁴, G.M. Flores³, S. González¹, D. Martínez², B. Cabello³, R. Espinoza³, O. Fernández³ | ¹Myeloma-clinic Hematology service, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México City, México; ²Myeloma-clinic Hematology service, Instituto Nacional de Nutrición Salvador Zubirán, México City, México; ³Myeloma-clinic Hematology service, Instituto Nacional de Cancerologçia, México City, Mexico; ⁴Centro Médico Nacional 20 de Noviembre, México City, Mexico

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.487

  115

  PDF: 30
• 

  PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS A. Naassan, R. Fatima, M. Naassan, C. Chisholm | Lakeridge Health, R.S. McLaughlin Durham Regional Cancer Centre, Department of Oncology, Oshawa, ON, Canada

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.548

  205

  PDF: 40
• 

  PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508^CAT O. Milberg¹, H. Abdallah¹, R.K. Lokken², R. Dingman¹, K.A. Meagher¹, P. Banerjee¹, M.E. Burczynski¹, E. Marin¹, A.P. Kithcart¹, D.E. Gutstein¹ | ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ²Allucent, Cary, NC, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.544

  103

  PDF: 30
• 

  PO16 | EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND OUTCOMES OF PROVOKED AND UNPROVOKED PULMONARY EMBOLISM IN A MULTICULTURAL ISRAELI POPULATION R. Farah¹, N.L. Bragazzi^2|3|4, H.İ. Ceylan⁵, Ł. Szarpak^6|7|8|9, W. Mahajni¹, N. Ashqar¹, A. M. Fioretti¹⁰, R. Khamisy-Farah¹¹ | ¹Internal Medicine B Department, Ziv Medical Center, Azrieli Faculty of Medicine, Bar-Ilan University, Galilee, Safed, Israel; ²Laboratory for Industrial and Applied Mathematics, Department of Mathematics and Statistics, York University, Toronto, Canada; ³Postgraduate School of Public Health, Department of Health Sciences, University of Genoa, Italy; ⁴UNESCO Chair, Health Anthropology, Biosphere and Healing Systems, University of Genoa, Italy; ⁵Physical Education and Sports Teaching Department, Faculty of Sports Sciences, Atatürk University, Erzurum, Turkey; ⁶Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland; ⁷Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, Lublin, Poland; ⁸The World Academic Council of Emergency Medicine, Sarasota, FL, USA; ⁹Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA; ¹⁰Cardio-Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy; ¹¹Clalit Health Service, Azrieli Faculty of Medicine, Bar-Ilan University, Galilee, Safed, Israel

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.511

  117

  PDF: 34
• 

  PO03 | HEPATIC FIBROSIS–DRIVEN TISSUE FACTOR EXPRESSION BY MALIGNANT CHOLANGIOCYTES IS ASSOCIATED WITH CANCER-ASSOCIATED THROMBOSIS AND POOR SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA L. Fabris^1|2|3, Y. Frión-Herrera¹, C. Venturin^1|3, M. Cadamuro⁴, J. Gasparello⁵, C. M. Radu^1|2, M. Fassan^1|5, C. Mescoli⁶, U. Cillo^7|8, E. Gringeri^7|8, G. Zanus^7|9, E. Campello^1|2, M. Strazzabosco³, P. Simioni^1|2 | ¹Department of Medicine, University of Padua; ²Clinical Medicine 1 and Thrombotic and Haemorrhagic Disease Unit, and Haemophilia Center, Padua University-Hospital; ³Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, CT, USA; ⁴School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; ⁵Pathology Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso; ⁶Pathology Unit, Padua University-Hospital; ⁷Department of Surgery, Oncology and Gastroenterology, University of Padua; ⁸Hepatobiliary Surgery and Liver Transplantation Unit, Padua University-Hospital; ⁹General Surgery Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.499

  115

  PDF: 24
• 

  PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508^CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker¹, M. P. O’Brien², M. Carrier³, J. Connors⁴, A. Falanga⁵, A. Manzano⁶, R. Mcbane⁷, Y.Y. Janjigian¹, G. O’Kane⁸, M. Onisko², J. Kaplan², A.P. Kithcart², D.E. Gutstein², A. Khorana⁹, M. F. Walsh² | ¹Memorial Sloan Kettering Cancer Center, New York, USA; ²Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; ³University of Ottawa, Ottawa, ON, Canada; ⁴Harvard Medical School, Boston, MA, USA; ⁵Hospital Papa Giovanni XXIII, Bergamo, Italy; ⁶Hospital Universitario 12 de Octubre, Madrid, Spain; ⁷Mayo Clinic, Rochester, MN, USA; ⁸St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; ⁹James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.545

  115

  PDF: 32
• 

  PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933^A2 AND REGN7508^CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker^1,2, A.P. Kithcart³, J. Kaplan³, Y-C. Cheng³, J.G. Raya³, J. Xiao³, S. Li³, K. Musgrave⁴, D.E. Gutstein³, G. Piazza⁵ | ¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Weill Cornell Medical Center, New York, NY, USA; ³Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; ⁴Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; ⁵Brigham and Women’s Hospital, Boston, MA, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.542

  121

  PDF: 30